Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
暂无分享,去创建一个
F. Baldanti | R. Maserati | G. Barbarini | P. Sacchi | S. Paolucci | A. Piralla | A. Silvestri | S. Novati | R. Gulminetti | F. Novazzi | Alice Fratini
[1] M. Milella,et al. Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[2] R. Sacco,et al. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis , 2019, Expert opinion on drug safety.
[3] Takanori Ito,et al. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] H. El‐Serag,et al. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents , 2019, Digestive Diseases and Sciences.
[5] K. Kerr,et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. , 2018, Journal of hepatology.
[6] Manal M. Hassan,et al. Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer , 2018, Journal of hepatocellular carcinoma.
[7] K. Hayashi,et al. Substitutions in interferon sensitivity‐determining region and hepatocarcinogenesis after hepatitis C virus eradication , 2018, Journal of gastroenterology and hepatology.
[8] Francesca Ceccherini-Silberstein,et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[9] Hussein H. Aly,et al. Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling , 2015, Oncotarget.
[10] F. Baldanti,et al. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs , 2017, Scientific Reports.
[11] J. Salmerón,et al. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment , 2017, World journal of gastroenterology.
[12] J. A. Patino-Galindo,et al. Comparative analysis of variation and selection in the HCV genome. , 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[13] Jean-Michel Pawlotsky,et al. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. , 2016, Gastroenterology.
[14] Christoph Sarrazin,et al. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. , 2016, Journal of hepatology.
[15] P. Saliou,et al. Duplication of the V3 domain in hepatitis C virus (1b) NS5A protein: Clonal analysis and physicochemical properties related to hepatocellular carcinoma occurrence. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[16] Takanori Ito,et al. Risk factors of hepatocellular carcinoma development in non‐cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection , 2015, Journal of gastroenterology and hepatology.
[17] M. Manns,et al. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? , 2014, Journal of hepatology.
[18] O. Weiland,et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] Y. Hiasa,et al. Protein Kinase R Modulates c-Fos and c-Jun Signaling to Promote Proliferation of Hepatocellular Carcinoma with Hepatitis C Virus Infection , 2013, PloS one.
[20] H. Nomura,et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. , 2013, Journal of hepatology.
[21] F. Baldanti,et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients , 2012, Virology Journal.
[22] A. Moya,et al. The role of positive selection in hepatitis C virus. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[23] M. Mondelli,et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. , 2009, Journal of hepatology.
[24] T. Hu,et al. Association of amino acid variations in the NS5A and E2‐PePHD region of hepatitis C virus 1b with hepatocellular carcinoma , 2007, Journal of viral hepatitis.
[25] Subash Das,et al. Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication. , 2006, The Journal of general virology.
[26] J. Bruix,et al. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV‐1b–related cirrhosis , 2001, Hepatology.
[27] R. Silverman,et al. RNA-Dependent Protein Kinase PKR Is Required for Activation of NF-κB by IFN-γ in a STAT1-Independent Pathway1 , 2001, The Journal of Immunology.
[28] B. Williams,et al. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin , 2000, The EMBO journal.
[29] M. Sata,et al. Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.
[30] S. Polyak,et al. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon‐sensitive virus replication , 1999, Hepatology.
[31] Michael G. Katze,et al. Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation , 1998, Molecular and Cellular Biology.